Evaluation of the Virclia<sup>®</sup> automated chemiluminescent immunoassay system for diagnosing pneumonia caused by <i>Mycoplasma pneumoniae</i>

Tabla, Victoria Ortiz de la; Berruezo, Marta; Payá, Elena García; Fernandez-González, Marta; García, José Alberto; Masiá, Mar; Gutiérrez, Félix

doi:10.1002/jcla.22431

Cited by 5 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, these data may spur the interest in confirming and extending seroprevalence studies in broader occupational exposed populations for better evaluating the clinical implications of these TBDs. Moreover, use of a single-assay chemiluminescent test system, which is very simple to perform and requires minimum sample handling, eliminates the need to make serum dilutions at high concentrations, avoids variations related to the conventional manual or semiautomatic techniques such as ELISA and seems to be a highly advantageous option for seroprevalence studies especially in occupational settings [ 62 ]. It could not be ruled out that cases of human TBDs may remain underdiagnosed because of the non-specific disease presentation and lack of awareness of physicians about their diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Seroprevalence of vector-borne pathogens in outdoor workers from southern Italy and associated occupational risk factors

et al. 2022

View full text Add to dashboard Cite

Background Vector-borne diseases (VBDs) represent an emerging global threat to public health due to the geographical expansion of arthropod vectors. The study aims to assess the seroprevalence of selected vector-borne pathogens (VBPs) in different groups of outdoor workers and the occupational risk factors for exposure to arthropod bites. Methods A cross-sectional study was conducted on 170 workers recruited in two different regions of southern Italy, including farmers, forestry workers, veterinarians, geologists/agronomists and administrative employees, and tested for IgG antibodies against Bartonella henselae, Borrelia spp. Coxiella burnetii and Rickettsia conorii, using a chemiluminescent immunoassay (CLIA). The relationship among job characteristics, tick exposure and the prevalence of seropositive subjects for each pathogen was investigated by applying categorical principal component analysis (CATPCA). Results A high seroprevalence for C. burnetii (30.0%) and R. conorii (15.3%) was reported, mainly in farmers (67.7% and 54.8%, respectively) and forestry workers (29.0% and 16.1%, respectively), while a low prevalence was observed for B. henselae and Borrelia spp. (8.8% and 4.1%, respectively). The regression equation by CATPCA was significant for C. burnetii and R. conorii (P < 0.001), showing a positive association with job, tick bite exposure, working area and contact with animals. Conclusions These findings highlight the need of activating an appropriate occupational health response for minimizing the risk of arthropod vector exposure in workplaces, considering specific preventive measures in particular in high-risk job categories. Graphical Abstract

show abstract

Section: Discussionmentioning

confidence: 99%

Seroprevalence of vector-borne pathogens in outdoor workers from southern Italy and associated occupational risk factors

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A novel chemiluminescent immunoassay system is replacing the conventional enzyme-linked immunosorbent assay (ELISA) to diagnose MP pneumonia [ 13 ]. The new chemiluminescent immunoassay is known to be quicker and have better analytic workability than the conventional ELISA [ 13 , 14 , 22 ]. Until now, studies have focused on comparing the chemiluminescent immunoassay with the conventional serologic tests for diagnosing MP pneumonia.…”

Section: Discussionmentioning

confidence: 99%

Predictive Factors of the Responses to Treatment of Mycoplasma pneumoniae Pneumonia

Lee

2021

JCM

View full text Add to dashboard Cite

The prevalence of refractory Mycoplasma pneumoniae (MP) pneumonia is increasing. The present study aimed to identify the predictive factors of responses to treatment of MP pneumonia in children. A total of 149 children were diagnosed with MP pneumonia, of whom 56 were included in the good response group, 75 children in the slow response group, and 18 children in no response or progression group. Data on the clinical, laboratory, and radiologic features were retrospectively obtained through medical chart reviews. The severity of pneumonia, based on the extent of pneumonic lesions on chest x-ray (adjusted odds ratio (aOR), 10.573; 95% confidence intervals (CIs), 2.303−48.543), and lactate dehydrogenase (LDH) levels (aOR, 1.002; 95% CIs, 1.000–1.004) at the time of admission were associated with slow response to treatment of MP pneumonia. Pleural effusion (aOR, 5.127; 95% CIs, 1.404–18.727), respiratory virus co-infection (aOR, 4.354; 95% CIs, 1.374–13.800), and higher LDH levels (aOR, 1.005; 95% CIs, 1.002–1.007) as well as MP-specific IgM titer (aOR, 1.309; 95% CIs, 1.095–1.564) were associated with no response or progression of MP pneumonia. The area under the curve for the prediction of no or poor response in MP pneumonia using pleural effusion, respiratory virus co-infection, LDH levels, and MP-specific IgM titer at the time of admission was 0.8547. This study identified the predictive factors of responses to treatment of MP pneumonia in children, which would be helpful in establishing a therapeutic plan and predicting the clinical course of MP pneumonia in children.

show abstract

“…Esta prueba consiste en un inmunoensayo quimioluminiscente de captura tipo sandwich (siglas CLIA en inglés) para detección de antígeno de galactomanano de Aspergillus en muestras humanas de suero, plasma y lavado broncoalveolar (LBA). La plataforma automatizada Virclia ® Lotus ha sido evaluada en el diagnóstico serológico de otras infecciones con buenos resultados 4,5 . Este es el primer estudio a publicar, que se realiza con la plataforma Virclia ® Lotus, para medición de galactomanano de Aspergillus en el medio nacional e internacional.…”

Section: Introductionunclassified

Evaluación de la prueba Aspergillus Galactomannan Ag VircliaR Monotest como alternativa a kit Platelia™ Aspergillus EIA

C.¹,

F²,

P³

et al. 2022

Rev. chil. infectol.

View full text Add to dashboard Cite

show abstract

Evaluation of the Virclia^® automated chemiluminescent immunoassay system for diagnosing pneumonia caused by Mycoplasma pneumoniae

Abstract: The accuracy of the Virclia assay for the diagnosis of M. pneumoniae infection in outpatients with CAP was equivalent to the quantitative ELISA. The CLIA was quicker to perform and displayed better analytic workability than conventional ELISA.

Cited by 5 publications

References 24 publications

Seroprevalence of vector-borne pathogens in outdoor workers from southern Italy and associated occupational risk factors

Seroprevalence of vector-borne pathogens in outdoor workers from southern Italy and associated occupational risk factors

Predictive Factors of the Responses to Treatment of Mycoplasma pneumoniae Pneumonia

Evaluación de la prueba Aspergillus Galactomannan Ag VircliaR Monotest como alternativa a kit Platelia™ Aspergillus EIA

Contact Info

Product

Resources

About

Evaluation of the Virclia® automated chemiluminescent immunoassay system for diagnosing pneumonia caused by Mycoplasma pneumoniae

Abstract: The accuracy of the Virclia assay for the diagnosis of M. pneumoniae infection in outpatients with CAP was equivalent to the quantitative ELISA. The CLIA was quicker to perform and displayed better analytic workability than conventional ELISA.

Cited by 5 publications

References 24 publications

Seroprevalence of vector-borne pathogens in outdoor workers from southern Italy and associated occupational risk factors

Seroprevalence of vector-borne pathogens in outdoor workers from southern Italy and associated occupational risk factors

Predictive Factors of the Responses to Treatment of Mycoplasma pneumoniae Pneumonia

Evaluación de la prueba Aspergillus Galactomannan Ag VircliaR Monotest como alternativa a kit Platelia&#8482; Aspergillus EIA

Contact Info

Product

Resources

About

Evaluation of the Virclia^® automated chemiluminescent immunoassay system for diagnosing pneumonia caused by Mycoplasma pneumoniae

Evaluación de la prueba Aspergillus Galactomannan Ag VircliaR Monotest como alternativa a kit Platelia™ Aspergillus EIA